The primary goal of this application is to obtain a detailed understanding of the structural requirements for selective and potent binding to the glutamate synaptic vesicular transporter (GVT) protein. The long-range goal of this study is to develop a pharmacophore model of the glutamate vesicular transporter protein and to utilize this information to regulate vesicular storage, uptake and release of glutamate or other compounds of interest. Although our overall knowledge of the glutamate neurotransmitter system has advanced significantly over the past two decades, particularly pharmacophore development at the receptors, surprisingly little is known about the glutamate synaptic vesicular transporter and very few competitive inhibitors have been identified. Potent and selective inhibitors are needed to better understand the GVT structure, function and regulation. The main strategy of this application is to merge key structural and functional group elements of known inhibitors with the natural substrate glutamate to design and synthesize new inhibitor molecules. Once identified, the new inhibitor library will be used to develop a pharmacophore model and prepare affinity ligands of the transporter. The following objectives are proposed: OBJECTIVE 1: A systematically designed library of substituted quinoline diacids, naphthylamine [di]sulfonic acids and hybrid quinoline/naphthylamine molecules will be synthesized that simulate key conformations of glutamate responsible for binding to the glutamate vesicular transporter. OBJECTIVE 2: To test the activity of compounds prepared in Objective 1 as inhibitors and substrates of the GVT. The ability of these compounds to bind EAA receptors and cellular transporters will be determined to assess the specificity of the action. OBJECTIVE 3: To conduct structure-activity and molecular modeling studies to generate a pharmacophore model of the glutamate vesicular transporter. Results obtained in this section will be used to refine inhibitor structure, provide feedback to for Objective 1 and develop an increasingly detailed model of the GVT binding domain. OBJECTIVE 4: To prepare reactive photoaffinity ligands that will be used to covalently modify the GVT to probe structure and function. OBJECTIVE 5: Inhibitors identified and characterized in Objective 2 will be used to begin to elucidate the role of vesicular transport in regulating levels of vesicularly released glutamate.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS038248-03
Application #
6394055
Study Section
Special Emphasis Panel (ZRG1-MDCN-3 (01))
Program Officer
Chiu, Arlene Y
Project Start
1999-09-01
Project End
2003-03-31
Budget Start
2001-09-01
Budget End
2003-03-31
Support Year
3
Fiscal Year
2001
Total Cost
$227,726
Indirect Cost
Name
University of Montana
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
City
Missoula
State
MT
Country
United States
Zip Code
59812
Stine, Jessica M; Ahl, Gabriel J H; Schlenker, Casey et al. (2017) The Interaction between the Third Type III Domain from Fibronectin and Anastellin Involves ?-Strand Exchange. Biochemistry 56:4667-4675
Carrigan, Christina N; Patel, Sarjubhai A; Cox, Holly D et al. (2014) The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroids. Bioorg Med Chem Lett 24:850-4
Ahmed, S Kaleem; Etoga, Jean-Louis G; Patel, Sarjubhai A et al. (2011) Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-). Bioorg Med Chem Lett 21:4358-62
Etoga, Jean-Louis G; Ahmed, S Kaleem; Patel, Sarjubhai et al. (2010) Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter. Bioorg Med Chem Lett 20:2680-3
Mullins, Jason E; Etoga, Jean-Louis G; Gajewski, Mariusz et al. (2009) Unexpected Formation of Highly Functionalized Dihydropyrans via Addition-Cyclization Reactions Between Dimethyl Oxoglutaconate and ?,?-Unsaturated Hydrazones. Tetrahedron Lett 50:2298-2300
Cox, Holly D; Thompson, Charles M (2008) Purification and proteomic analysis of synaptic vesicles. Methods Mol Biol 432:259-74
Cox, Holly D; Chao, Chih-Kai; Patel, Sarjubhai A et al. (2008) Efficient digestion and mass spectral analysis of vesicular glutamate transporter 1: a recombinant membrane protein expressed in yeast. J Proteome Res 7:570-8
Patel, Sarjubhai A; Nagy, Jon O; Bolstad, Erin D et al. (2007) Tetrapeptide inhibitors of the glutamate vesicular transporter (VGLUT). Bioorg Med Chem Lett 17:5125-8
Thompson, Charles M; Davis, Erin; Carrigan, Christina N et al. (2005) Inhibitor of the glutamate vesicular transporter (VGLUT). Curr Med Chem 12:2041-56
Bunik, Victoria I; Denton, Travis T; Xu, Hui et al. (2005) Phosphonate analogues of alpha-ketoglutarate inhibit the activity of the alpha-ketoglutarate dehydrogenase complex isolated from brain and in cultured cells. Biochemistry 44:10552-61

Showing the most recent 10 out of 15 publications